These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 33939675)

  • 1. Genetic Variants in Patients With a Family History of Pancreatic Cancer: Impact of Multigene Panel Testing.
    Zhu H; Welinsky S; Soper ER; Brown KL; Abul-Husn NS; Lucas AL
    Pancreas; 2021 Apr; 50(4):602-606. PubMed ID: 33939675
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Statewide Retrospective Review of Familial Pancreatic Cancer in Delaware, and Frequency of Genetic Mutations in Pancreatic Cancer Kindreds.
    Catts ZA; Baig MK; Milewski B; Keywan C; Guarino M; Petrelli N
    Ann Surg Oncol; 2016 May; 23(5):1729-35. PubMed ID: 26727920
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prospective study of germline genetic testing in incident cases of pancreatic adenocarcinoma.
    Brand R; Borazanci E; Speare V; Dudley B; Karloski E; Peters MLB; Stobie L; Bahary N; Zeh H; Zureikat A; Hogg M; Lee K; Tsung A; Rhee J; Ohr J; Sun W; Lee J; Moser AJ; DeLeonardis K; Krejdovsky J; Dalton E; LaDuca H; Dolinsky J; Colvin A; Lim C; Black MH; Tung N
    Cancer; 2018 Sep; 124(17):3520-3527. PubMed ID: 30067863
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of a Variety of Mutations in Cancer Predisposition Genes in Patients With Suspected Lynch Syndrome.
    Yurgelun MB; Allen B; Kaldate RR; Bowles KR; Judkins T; Kaushik P; Roa BB; Wenstrup RJ; Hartman AR; Syngal S
    Gastroenterology; 2015 Sep; 149(3):604-13.e20. PubMed ID: 25980754
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multigene Panel Testing Detects Equal Rates of Pathogenic BRCA1/2 Mutations and has a Higher Diagnostic Yield Compared to Limited BRCA1/2 Analysis Alone in Patients at Risk for Hereditary Breast Cancer.
    Kapoor NS; Curcio LD; Blakemore CA; Bremner AK; McFarland RE; West JG; Banks KC
    Ann Surg Oncol; 2015 Oct; 22(10):3282-8. PubMed ID: 26219241
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The spectrum of genetic variants in hereditary pancreatic cancer includes Fanconi anemia genes.
    Slavin TP; Neuhausen SL; Nehoray B; Niell-Swiller M; Solomon I; Rybak C; Blazer K; Adamson A; Yang K; Sand S; Guerrero-Llamas N; Castillo D; Herzog J; Wu X; Tao S; Raja S; Chung V; Singh G; Nadesan S; Brown S; Cruz-Correa M; Petersen GM; Weitzel J;
    Fam Cancer; 2018 Apr; 17(2):235-245. PubMed ID: 28687971
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Disparate Rates of Germline Variants in Cancer Predisposition Genes in African American/Black Compared With Non-Hispanic White Individuals Between 2015 and 2022.
    Wyatt Castillo RB; Nielsen SM; Chen E; Heald B; Ellsworth RE; Esplin ED; Tomlinson GE
    JCO Precis Oncol; 2024 Jul; 8():e2300715. PubMed ID: 38991178
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Burden of hereditary cancer susceptibility in unselected patients with pancreatic ductal adenocarcinoma referred for germline screening.
    Cremin C; Lee MK; Hong Q; Hoeschen C; Mackenzie A; Dixon K; McCullum M; Nuk J; Kalloger S; Karasinska J; Scudamore C; Kim PTW; Donnellan F; Lam ECS; Lim HJ; Neben CL; Stedden W; Zhou AY; Schaeffer DF; Sun S; Renouf DJ; Schrader KA
    Cancer Med; 2020 Jun; 9(11):4004-4013. PubMed ID: 32255556
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Germline mutation prevalence in individuals with pancreatic cancer and a history of previous malignancy.
    Dudley B; Karloski E; Monzon FA; Singhi AD; Lincoln SE; Bahary N; Brand RE
    Cancer; 2018 Apr; 124(8):1691-1700. PubMed ID: 29360161
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Unexpected actionable genetic variants revealed by multigene panel testing of patients with uterine cancer.
    Heald B; Mokhtary S; Nielsen SM; Rojahn S; Yang S; Michalski ST; Esplin ED
    Gynecol Oncol; 2022 Aug; 166(2):344-350. PubMed ID: 35691755
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical Impact of Pathogenic Germline Variants in Pancreatic Cancer: Results From a Multicenter, Prospective, Universal Genetic Testing Study.
    Uson PLS; Samadder NJ; Riegert-Johnson D; Boardman L; Borad MJ; Ahn D; Sonbol MB; Faigel DO; Fukami N; Pannala R; Kunze K; Golafshar M; Klint M; Esplin ED; Nussbaum RL; Stewart AK; Bekaii-Saab T
    Clin Transl Gastroenterol; 2021 Oct; 12(10):e00414. PubMed ID: 34620795
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Referral frequency, attrition rate, and outcomes of germline testing in patients with pancreatic adenocarcinoma.
    Walker EJ; Carnevale J; Pedley C; Blanco A; Chan S; Collisson EA; Tempero MA; Ko AH
    Fam Cancer; 2019 Apr; 18(2):241-251. PubMed ID: 30267352
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical Management of Patients at Risk for Hereditary Breast Cancer with Variants of Uncertain Significance in the Era of Multigene Panel Testing.
    Chang J; Seng S; Yoo J; Equivel P; Lum SS
    Ann Surg Oncol; 2019 Oct; 26(10):3389-3396. PubMed ID: 31342386
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of Multigene Panel Testing on Surgical Decision Making in Breast Cancer Patients.
    Pederson HJ; Gopalakrishnan D; Noss R; Yanda C; Eng C; Grobmyer SR
    J Am Coll Surg; 2018 Apr; 226(4):560-565. PubMed ID: 29360614
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevalence and spectrum of pathogenic germline variants in intestinal and pancreatobiliary type of ampullary cancer.
    Kumari N; Singh RK; Mishra SK; L R; Mohindra S; Krishnani N
    Pathol Res Pract; 2021 Jan; 217():153309. PubMed ID: 33341547
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rate of Pathogenic Germline Variants in Patients With Lung Cancer.
    Sorscher S; LoPiccolo J; Heald B; Chen E; Bristow SL; Michalski ST; Nielsen SM; Lacoste A; Keyder E; Lee H; Nussbaum RL; Martins R; Esplin ED
    JCO Precis Oncol; 2023 Sep; 7():e2300190. PubMed ID: 37992258
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevalence and clinical implications of germline mutations among Jordanian patients with ovarian cancer. The Jordanian exploratory cancer genetics (Jo-ECAG) ovarian study.
    Abdel-Razeq H; Al-Azzam K; Elemian S; Abu-Fares H; Abu Sheikha A; Bani Hani H; Bater R; Sharaf B; Heald B; Esplin ED; Nielsen SM; Alkyam M; Abujamous L; Al-Attary A
    Mol Genet Genomic Med; 2023 Apr; 11(4):e2125. PubMed ID: 36537080
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Outcome of Pancreatic Cancer Surveillance Among High-Risk Individuals Tested for Germline Mutations in
    Saldia A; Olson SH; Nunes P; Liang X; Samson ML; Salo-Mullen E; Marcell V; Stadler ZK; Allen PJ; Offit K; Kurtz RC
    Cancer Prev Res (Phila); 2019 Sep; 12(9):599-608. PubMed ID: 31337648
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mainstreaming germline genetic testing for patients with pancreatic cancer increases uptake.
    Ramsey ML; Tomlinson J; Pearlman R; Abushahin L; Aeilts A; Chen HZ; Chen Y; Compton A; Elkhatib R; Geiger L; Hays J; Jeter J; Jin N; Malalur P; Roychowdhury S; Ruple J; Prebish J; Stanich PP; Hampel H
    Fam Cancer; 2023 Jan; 22(1):91-97. PubMed ID: 35713757
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Family communication and patient distress after germline genetic testing in individuals with pancreatic ductal adenocarcinoma.
    Peters MLB; Stobie L; Dudley B; Karloski E; Allen K; Speare V; Dolinsky JS; Tian Y; DeLeonardis K; Krejdovsky J; Button A; Lim C; Borazanci E; Brand R; Tung N
    Cancer; 2019 Jul; 125(14):2488-2496. PubMed ID: 30980401
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.